About
Bright Minds Biosciences Inc (CN:DRUG) — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 9 2026
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Jan 8 2026
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Jan 6 2026
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
Jan 6 2026
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Jan 5 2026
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Financials
Revenue
CA$0
Market Cap
CA$958.75 M
EPS
-2.76